388 related articles for article (PubMed ID: 31836624)
1. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
2. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II
Carvajal-Moreno J; Hernandez VA; Wang X; Li J; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2023 Feb; 384(2):265-276. PubMed ID: 36410793
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Genome Editing of the Human Topoisomerase II
Hernandez VA; Carvajal-Moreno J; Papa JL; Shkolnikov N; Li J; Ozer HG; Yalowich JC; Elton TS
Mol Pharmacol; 2021 Mar; 99(3):226-241. PubMed ID: 33446509
[TBL] [Abstract][Full Text] [Related]
4. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
5. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
[TBL] [Abstract][Full Text] [Related]
6. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
7. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Chen CF; He X; Arslan AD; Mo YY; Reinhold WC; Pommier Y; Beck WT
Mol Pharmacol; 2011 Apr; 79(4):735-41. PubMed ID: 21252292
[TBL] [Abstract][Full Text] [Related]
8. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract][Full Text] [Related]
9.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
10. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
11. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
13. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells.
Melixetian MB; Beryozkina EV; Pavlenko MA; Grinchuk TM
Leuk Res; 2000 Oct; 24(10):831-7. PubMed ID: 10996201
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
16. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
[TBL] [Abstract][Full Text] [Related]
18. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
19. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
20. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]